Clinical trials: Amyotrophic Lateral Sclerosis, Sporadic
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS
Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutation status is often unknown.
- Trial name
- ID-ALS (NCT05852405)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Ambulanzpartner Soziotechnologie APST GmbH
Sporadic Amyotrophic Lateral Sclerosis
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- MX-ALS-001 (NCT01849770)
- Testing
- Mexiletine
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Washington
Amyotrophic Lateral Sclerosis
iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study
This study consists of a phase 1 part and a phase 2 part. Phase 1 part: This is a phase 1, open-label, multicenter, dose escalation study to evaluate the safety and tolerability of bosutinib to determine the maximum tolerated…
- Trial name
- NCT04744532
- Testing
- Bosutinib (Phase 1 part), Bosutinib (Phase 2 part)
- Where
- 7 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Kyoto University
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
ALS
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis…
- Trial name
- LUMINA (NCT06665165)
- Testing
- AMX0114
- Where
- 14 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis, Familial, Amyotrophic Lateral Sclerosis, Sporadic
SOD1 Kinetics Measurements in ALS Patients
Washington University in St. Louis is seeking participants with ALS for a study to determine the half-life of the protein SOD1 in the cerebral spinal fluid.
- Trial name
- NCT03449212
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Sporadic Amyotrophic Lateral Sclerosis
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
The purpose of this research study is to find out whether the drug mexiletine will be effective in lowering motor neuron electrical activity in the brains and nerves in the arms of people with ALS.
- Trial name
- Mexiletine-2 (NCT02781454)
- Testing
- Mexiletine
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis
Genetics of Familial and Sporadic ALS
We are collecting blood samples, clinical and family information from ALS (amyotrophic lateral sclerosis) patients and their families to identify causes of ALS and ALS/dementia.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Familial Amyotrophic Lateral Sclerosis, ALS With Frontotemporal Dementia (ALS/FTD), Lou Gehrig's Disease
- Trial name
- ALS (NCT00821132)
- Testing
- Genetic study of ALS families
- Where
- United States
- Volunteers
- 13,521 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Amyotrophic Lateral Sclerosis
A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)
Single ascending doses of AP-101 will be administered by intravenous (IV) infusion
- Trial name
- NCT03981536
- Testing
- AP-101
- Where
- 3 sites in Canada
- Volunteers
- 18 people
- Sponsor
- AL-S Pharma
Amyotrophic Lateral Sclerosis
A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)
The primary purpose of this study is to evaluate the safety and tolerability of VRG50635 in participants with ALS.
- Trial name
- NCT06215755
- Testing
- VRG50635
- Where
- 7 sites in Belgium, Canada and 2 more
- Volunteers
- 54 people
- Sponsor
- Verge Genomics
Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic
Dual Treatment With Lithium and Valproate in ALS.
This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate and lithium carbonate. After a random assignation of the dual treatment vs.
- Trial name
- NCT03204500
- Testing
- Active treatment with dual therapy
- Where
- Mexico
- Volunteers
- 43 people
- Sponsor
- El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
ALS
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)
To investigate the safety and the efficacy of perampanel in patients with sporadic amyotrophic lateral sclerosis
- Trial name
- NCT03019419
- Testing
- Perampanel
- Where
- 12 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Tokyo Medical University
Amyotrophic Lateral Sclerosis
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The main purpose of this study is to assess the long-term safety and tolerability of LY4256984 in participants with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT07571174
- Testing
- LY4256984
- Where
- 11 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Sporadic Amyotrophic Lateral Sclerosis
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown.
- Trial name
- Fibro-ALS (NCT02969759)
- Testing
- Skin Biopsy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Primary Lateral Sclerosis
Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of…
- Trial name
- NCT00015444
- Where
- United States
- Volunteers
- 189 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene.
- Trial name
- NCT02686268
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 128 people
- Sponsor
- Washington University School of Medicine
Amyotrophic Lateral Sclerosis, Sporadic, Amyotrophic Lateral Sclerosis
ALS Diagnosis From a Saliva Sample: a Non-coding RNA Analysis Approach
RNALS is a multicentre, transversal, diagnostic and non-interventional study carried out in ALS reference centers; in order to identify a diagnostic signature for Amyotrophic Lateral Sclerosis by analyzing of coding and…
- Trial name
- RNALS (NCT05928416)
- Testing
- Saliva sample
- Where
- 19 sites in France
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- ZIWIG
Amyotrophic Lateral Sclerosis
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
- Trial name
- NCT05039099
- Testing
- AP-101
- Where
- 13 sites in United States, Belgium and 4 more
- Volunteers
- 73 people
- Sponsor
- AL-S Pharma
ALS (Amyotrophic Lateral Sclerosis)
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07100119
- Testing
- LY4256984
- Where
- 12 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company